Gene silencing of indoleamine 2,3‑dioxygenase 1 inhibits lung cancer growth by suppressing T‑cell exhaustion

Shang,Ke; Wang,Zhigang; Hu,Yinying; Huang,Yanqin; Yuan,Keng; Yu,Yanrong

doi:10.3892/ol.2020.11477

Gene silencing of indoleamine 2,3‑dioxygenase 1 inhibits lung cancer growth by suppressing T‑cell exhaustion

Authors:
- Ke Shang
- Zhigang Wang
- Yinying Hu
- Yanqin Huang
- Keng Yuan
- Yanrong Yu
View Affiliations

Affiliations: Department of Rheumatology and Immunology, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Immunology, Jiangxi Academy of Medical Sciences, Nanchang, Jiangxi 330006, P.R. China
Published online on: March 27, 2020 https://doi.org/10.3892/ol.2020.11477
Pages: 3827-3838
Copyright: © Shang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Indoleamine 2,3-dioxygenase 1 (IDO1), which degrades the essential amino acid tryptophan, exerts immunosuppressive functions and serves a crucial role in multiple types tumor progression, including non‑small‑cell lung cancer (NSCLC) and melanoma. Recent studies have reported that T‑cell exhaustion is increased during tumor progression, which impairs the antitumor immune response. However, the association between IDO1 and T‑cell exhaustion during tumor progression remains unknown. The present study evaluated the effect of IDO1 on T‑cell exhaustion in lung cancer mice. The present study demonstrated that IDO1 knockdown by small interfering RNA in the LLC cell line inhibited T‑cell exhaustion. Furthermore, the role of IDO1 in T‑cell exhaustion during lung cancer progression was determined in an in vivo mouse model using IDO1 short hairpin RNA (shRNA). The results demonstrated that inhibition of IDO1 activity by shRNA administration in vivo significantly delayed the onset and growth of tumors. In addition, the expression levels of the inhibitory receptors programmed death‑1 (PD‑1) and B and T lymphocyte attenuator (BTLA) were increased in T‑cells from the lung tumor‑bearing mice, whereas interleukin‑2 (IL‑2) and tumor necrosis factor‑alpha (TNF‑α) levels in serum were decreased compared with the control mice. However, no difference in the absolute number of T cells was observed, including CD4+ and CD8+ T cells. In addition, IDO1 knockdown by shRNA inhibited T‑cell exhaustion in lung tumor‑bearing mice, which was characterized by decreased expression of PD‑1 and BTLA on T cells. By contrast, IL‑2 and TNF‑α levels in serum were increased in IDO1‑shRNA‑treated mice. By using a shRNA approach, the present study demonstrated that IDO1 activity may be involved in tumor growth, and that IDO1 silencing may inhibit tumor progression by impeding the process of T‑cell exhaustion.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Speeckaert R, Vermaelen K, van Geel N, Autier P, Lambert J, Haspeslagh M, van Gele M, Thielemans K, Neyns B, Roche N, et al: Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer. 48:2004–2011. 2012. View Article : Google Scholar : PubMed/NCBI
3	Platten M, von Knebel Doeberitz N, Oezen I, Wick W and Ochs K: Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol. 5:6732014.PubMed/NCBI
4	Munn DH and Mellor AL: Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34:137–143. 2013. View Article : Google Scholar : PubMed/NCBI
5	Munn DH and Mellor AL: IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance. Trends Immunol. 37:193–207. 2016. View Article : Google Scholar : PubMed/NCBI
6	Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, et al: IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2:722–735. 2012. View Article : Google Scholar : PubMed/NCBI
7	Que Z, Zou F, Zhang A, Zheng Y, Bi L, Zhong J, Tian J and Liu J: Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells. Int Immunopharmacol. 23:192–204. 2014. View Article : Google Scholar : PubMed/NCBI
8	Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD and Ahmed R: Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 188:2205–2213. 1998. View Article : Google Scholar : PubMed/NCBI
9	Pauken KE and Wherry EJ: Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36:265–276. 2015. View Article : Google Scholar : PubMed/NCBI
10	Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
11	Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V and Zarour HM: CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72:887–896. 2012. View Article : Google Scholar : PubMed/NCBI
12	Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al: Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 107:7875–7880. 2010. View Article : Google Scholar : PubMed/NCBI
13	Wherry EJ: T cell exhaustion. Nat Immunol. 12:492–499. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yi JS, Cox MA and Zajac AJ: T-cell exhaustion: Characteristics, causes and conversion. Immunology. 129:474–481. 2010. View Article : Google Scholar : PubMed/NCBI
15	Balkhi MY, Ma Q, Ahmad S and Junghans RP: T cell exhaustion and Interleukin 2 downregulation. Cytokine. 71:339–347. 2015. View Article : Google Scholar : PubMed/NCBI
16	Li S, Zhang S, Liu J, Yang C, Zhang L and Cheng Y: The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: A meta-analysis of randomized controlled clinical trials. J Thorac Dis. 11:4453–4463. 2019. View Article : Google Scholar : PubMed/NCBI
17	Yoon JS, Song JH, Yoon JH, Lee HY, Kim SW, Chang Y, Lee YB, Cho EJ, Yu SJ, Sinn DH, et al: Adjuvant cytokine-induced killer immunotherapy for hepatocellular carcinoma: A propensity score-matched analysis of real-world data. BMC Cancer. 19:5232019. View Article : Google Scholar : PubMed/NCBI
18	Bu X, Yao Y and Li X: Immune checkpoint blockade in breast cancer therapy. Adv Exp Med Biol. 1026:383–402. 2017. View Article : Google Scholar : PubMed/NCBI
19	Mirzaei R, Sarkar S and Yong VW: T cell exhaustion in glioblastoma: Intricacies of immune checkpoints. Trends Immunol. 38:104–115. 2017. View Article : Google Scholar : PubMed/NCBI
20	Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet. 384:1109–1117. 2014. View Article : Google Scholar : PubMed/NCBI
21	O'Connor JM, Seidl-Rathkopf K, Torres AZ, You P, Carson KR, Ross JS and Gross CP: Disparities in the use of programmed death 1 immune checkpoint inhibitors. Oncologist. 23:1388–1390. 2018. View Article : Google Scholar : PubMed/NCBI
22	Teo MY and Rosenberg JE: Nivolumab for the treatment of urothelial cancers. Expert Rev Anticancer Ther. 18:215–221. 2018. View Article : Google Scholar : PubMed/NCBI
23	Harris-Bookman S, Mathios D, Martin AM, Xia Y, Kim E, Xu H, Belcaid Z, Polanczyk M, Barberi T, Theodros D, et al: Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. Int J Cancer. 143:3201–3208. 2018. View Article : Google Scholar : PubMed/NCBI
24	Qin S, Xu L, Yi M, Yu S, Wu K and Luo S: Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Mol Cancer. 18:1552019. View Article : Google Scholar : PubMed/NCBI
25	Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH and Antonia SJ: Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 101:151–155. 2002. View Article : Google Scholar : PubMed/NCBI
26	Schafer CC, Wang Y, Hough KP, Sawant A, Grant SC, Thannickal VJ, Zmijewski J, Ponnazhagan S and Deshane JS: Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget. 7:75407–75424. 2016. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Pan J, Yuan K, Peng S, Huang Y, Zhang Y, Hu Y, Feng Y, Shi Y, Liu Y, Wang H, et al: Gene silencing of indoleamin 2,3-dioxygenase hinders tumor growth through angiogenesis inhibition. Int J Oncol. 50:2136–2144. 2017. View Article : Google Scholar : PubMed/NCBI
29	Naito S, von Eschenbach AC, Giavazzi R and Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 46:4109–4115. 1986.PubMed/NCBI
30	Escoffre JM, Novell A, Serrière S, Lecomte T and Bouakaz A: Irinotecan delivery by microbubble-assisted ultrasound: In vitro validation and a pilot preclinical study. Mol Pharm. 10:2667–2675. 2013. View Article : Google Scholar : PubMed/NCBI
31	American Veterinary Medical Association (AVMA), . AVMA Guidelines for the Euthanasia of Animals: 2013 Edition. AVMA; Schaumburg, IL: 2013
32	Powell K, Ethun K and Taylor DK: The effect of light level, CO₂ flow rate, and anesthesia on the stress response of mice during CO₂ euthanasia. Lab Anim (NY). 45:386–395. 2016. View Article : Google Scholar : PubMed/NCBI
33	Li Q, Johnston N, Zheng X, Wang H, Zhang X, Gao D and Min W: miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget. 7:53735–53750. 2016.PubMed/NCBI
34	Thommen DS and Schumacher TN: T cell dysfunction in cancer. Cancer Cell. 33:547–562. 2018. View Article : Google Scholar : PubMed/NCBI
35	Muller AJ and Prendergast GC: Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets. 7:31–40. 2007. View Article : Google Scholar : PubMed/NCBI
36	Zhang Y, Fu J, Shi Y, Peng S, Cai Y, Zhan X, Song N, Liu Y, Wang Z, Yu Y, et al: A new cancer immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene silencing using an immune-stimulatory nanosystem. Int J Cancer. 143:2039–2052. 2018. View Article : Google Scholar : PubMed/NCBI
37	Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, Gritsina G, Sun X, Liu Y, Yu F, et al: IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin Cancer Res. 24:2559–2573. 2018. View Article : Google Scholar : PubMed/NCBI
38	Jiang T, Sun Y, Yin Z, Feng S, Sun L and Li Z: Research progress of indoleamin 2,3-dioxygenase inhibitors. Future Med Chem. 7:185–201. 2015. View Article : Google Scholar : PubMed/NCBI
39	Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811. 1998. View Article : Google Scholar : PubMed/NCBI
40	Vakili S, Ebrahimi SS, Sadeghi A, Gorgani-Firuzjaee S, Beigy M, Pasalar P and Meshkani R: Hydrodynamic-based delivery of PTP1B shRNA reduces plasma glucose levels in diabetic mice. Mol Med Rep. 7:211–216. 2013. View Article : Google Scholar : PubMed/NCBI
41	Amezquita RA and Kaech SM: Immunology: The chronicles of T-cell exhaustion. Nature. 543:190–191. 2017. View Article : Google Scholar : PubMed/NCBI
42	Prall F and Hühns M: The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the ‘immunoreactive’ microenvironment of colorectal carcinoma. Histopathology. 71:366–374. 2017. View Article : Google Scholar : PubMed/NCBI
43	Yost KE, Spantidea PI, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA, et al: Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 25:1251–1259. 2019. View Article : Google Scholar : PubMed/NCBI
44	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
45	Paulos CM and June CH: Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. J Clin Invest. 120:76–80. 2010. View Article : Google Scholar : PubMed/NCBI
46	Karakatsanis S, Bertsias G, Roussou P and Boumpas D: Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: Brief review. Hematol Oncol. 32:113–119. 2014. View Article : Google Scholar : PubMed/NCBI
47	Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
48	Mittal R, Chen CW, Lyons JD, Margoles LM, Liang Z, Coopersmith CM and Ford ML: Murine lung cancer induces generalized T-cell exhaustion. J Surg Res. 195:541–549. 2015. View Article : Google Scholar : PubMed/NCBI
49	Hu CY, Zhang YH, Wang T, Chen L, Gong ZH, Wan YS, Li QJ, Li YS and Zhu B: Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer. Clin Exp Immunol. 186:106–114. 2016. View Article : Google Scholar : PubMed/NCBI
50	Khalil DN, Suek N, Campesato LF, Budhu S, Redmond D, Samstein RM, Krishna C, Panageas KS, Capanu M, Houghton S, et al: In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. J Clin Invest. 129:3435–3447. 2019. View Article : Google Scholar : PubMed/NCBI